

Posaconazole

Restricted Antimicrobial See CUH Antimicrobial Guidelines on Eolas for further information	
CAUTION: High Administration Risk Rating	
Form & Storage	300mg in 16.7ml Vials should be stored in a fridge (2°C-8°C)
Reconstitution	Already in solution
Compatibility and Stability	Sodium chloride 0.9% Glucose 5%
Administration	<p><u>IV Infusion</u> Add 16.7ml of posaconazole solution to 250ml of compatible infusion fluid and administer over 90 minutes via a central line or PICC. Concentration range 1-2mg/ml</p> <p>Note: If a central line is unavailable a <u>single</u> infusion can be given peripherally via a large vein: Add 16.7ml of posaconazole solution to 133ml of compatible infusion fluid (by removing 117ml from a 250ml bag) and administer over 30 minutes (concentration 2mg/ml)</p> <p>Note: In clinical studies, multiple peripheral infusions given through the same vein resulted in infusion site reactions</p> <p>Prepared infusions should be used immediately, if not used immediately prepared infusions can be stored for 24 hours in a fridge between 2-8°C</p> <p>Review to switch to oral route of administration as soon as the patient's condition allows. Consult Eolas for dosing-tablets and liquid available. Note: oral formulations are not interchangeable</p>
Extravasation	Extravasation may cause tissue damage due to a low pH
Monitoring & Adverse Drug Reactions	<ul style="list-style-type: none"> Posaconazole is usually prescribed as a loading dose (first 24 hours) followed by a maintenance dose (after first 24 hours) Never administer posaconazole as an IV bolus Posaconazole given peripherally can result in infusion site reactions/phlebitis, monitor site of injection Adverse effects include: fever, arrhythmias, thrombosis, infusion site reactions, hypersensitivity and allergic reactions Monitor blood pressure, heart rate, temperature, ECG (in high risk patients) The excipient betadex sulfobutyl ether sodium may accumulate in patients with moderate to severe renal impairment (eGFR <50ml/min). Monitor renal function and review route of administration regularly

Information provided relates to Noxafil manufactured by MSD